secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-07-20T12:07:21+00:00
Accession:  0001193125-26-308382
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris appoints Liisa Bayko as CFO; CAO Brett Hagen resigns
------------------------------------------------------------

- Liisa Bayko appointed CFO and Treasurer effective July 20, 2026; base salary $475,000, target bonus 40%, option for 220,000 shares.
- Brett Hagen resigns as SVP Finance and Chief Accounting Officer effective July 27, 2026.
- Amy Vandekop, Corporate Controller, designated interim principal accounting officer effective July 27, 2026.
- Bayko's option vests 25% on first anniversary, then monthly over 3 years; severance includes 9-12 months salary depending on change in control.
- Bayko previously Managing Director at Evercore ISI and JMP Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526308382/0001193125-26-308382-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526308382/d125092d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-308382

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer